, Volume 65, Issue 9, pp 1283–1291 | Cite as


In Ankylosing Spondylitis
  • Dean M. RobinsonEmail author
  • Gillian M. Keating
Adis Drug Profile


▴ Infliximab is a monoclonal antibody that binds to tumour necrosis factor-α and blocks its biological activity. It is approved for use in patients with rheumatoid arthritis, Crohn’s disease and ankylosing spondylitis.

▴ In well designed, placebo-controlled trials of 12 or 24 weeks’ duration in patients with active ankylosing spondylitis, more infliximab 5 mg/kg recipients achieved a response than placebo recipients according to Ankylosing Spondylitis Assessment Study 20% (61.2% vs 19.2%) or Bath Ankylosing Spondylitis Disease Activity Index 50% (53% vs 9%) criteria (primary endpoints).

▴ Infliximab was also superior to placebo in terms of various secondary clinical endpoints and in reducing spinal inflammation (as assessed by magnetic resonance imaging).

▴ Prolonged efficacy has been demonstrated in patients with ankylosing spondylitis who received infliximab for up to 3 years.

▴ Infliximab is generally well tolerated in patients with ankylosing spondylitis, with most adverse events being of mild-to-moderate severity.


Infliximab Ankylose Spondylitis Placebo Recipient Spondylitis Bath Ankylose Spondylitis Disease Activity Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Sieper J, Braun J. Anti-TNF agents for the treatment of spondyloarthropathies. Expert Opin Emerg Drugs 2002; 7(2): 235–46PubMedCrossRefGoogle Scholar
  2. 2.
    Braun J, Sieper J. Biological therapies in the spondyloarthritides: the current state. Rheumatology (Oxford) 2004 Sep; 43(9): 1072–84CrossRefGoogle Scholar
  3. 3.
    European Agency for the Evaluation of Medicinal Products. Remicade [online]. Available from URL: [Accessed 2005 Jan 10]
  4. 4.
    Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn’s disease and rheumatoid arthritis. Biodrugs 2002; 16(2): 111–48PubMedCrossRefGoogle Scholar
  5. 5.
    Braun J, Pham T, Sieper J, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003 Sep; 62(9): 817–24PubMedCrossRefGoogle Scholar
  6. 6.
    Braun J, Xiang J, Brandt J, et al. Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: first clinical and laboratory experiences. Ann Rheum Dis 2000; 59 Suppl. 1: i85–9PubMedCrossRefGoogle Scholar
  7. 7.
    Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-α, IL-1β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994 Oct; 33(10): 927–31PubMedCrossRefGoogle Scholar
  8. 8.
    Zou JX, Braun J, Sieper J. Immunological basis for the use of TNFα-blocking agents in ankylosing spondylitis and immunological changes during treatment. Clin Exp Rheumatol 2002 Nov–Dec; 20 (6 Suppl. 28): S34–7PubMedGoogle Scholar
  9. 9.
    US Food and Drug Administration. Prescribing information: Remicade® (infliximab) for IV injection [online]. Available from URL: [Accessed 2005 Jan 10]
  10. 10.
    Wagner C, Mace K, deWoody K. Infliximab treatment benefits correlate with pharmacodynamic parameters in Crohn’s disease patients. Digestion 1998; 59 Suppl. 3: 124–5Google Scholar
  11. 11.
    Zou J, Rudwaleit M, Brandt J, et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48(3): 780–90PubMedCrossRefGoogle Scholar
  12. 12.
    Baeten D, Vandooren B, De Rycke L, et al. Effect of infliximab treatment on T cell cytokine responses in spondylarthropathy: comment on the article by Zou et al. [letter]. Arthritis Rheum 2004; 50(3): 1015–7PubMedCrossRefGoogle Scholar
  13. 13.
    Yang C, Gu J, Rihl M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004 Oct; 51(5): 691–9PubMedCrossRefGoogle Scholar
  14. 14.
    Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994 Dec; 21(12): 2286–91PubMedGoogle Scholar
  15. 15.
    Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor α blockade in spondylarthropathy. Arthritis Rheum 2004 Sep; 50(9): 2942–53PubMedCrossRefGoogle Scholar
  16. 16.
    Boyle A, Tawadros R, Zhu Y, et al. Comparative pharmacokinetics of single and multiple-dose infliximab in Crohn’s disease patients [abstract no. W1349]. Gastroenterology 2002 Apr; 122 Suppl. 1: A614–5. Plus poster presented at Digestive Disease Week and the 103rd Annual Meeting of the American Gastroenterological Association; 2002 May 19–23; San FranciscoGoogle Scholar
  17. 17.
    Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 Sep; 41(9): 1552–63PubMedCrossRefGoogle Scholar
  18. 18.
    Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002 Apr 6; 359: 1187–93PubMedCrossRefGoogle Scholar
  19. 19.
    van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005 Feb; 52(2): 582–91PubMedCrossRefGoogle Scholar
  20. 20.
    Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003 Apr; 48(4): 1126–36PubMedCrossRefGoogle Scholar
  21. 21.
    Braun J, Landewé R, Hermann K-G, et al. The effect of infliximab therapy on spinal inflammation assessed by magnetic resonance imaging in a randomized, placebo-controlled trial of 279 patients with ankylosing spondylitis [abstract no. L21]. Presented at 68th Annual Meeting of the American College of Rheumatology; 2004 Oct 16–21; San Antonio [online]. Available from URL: [Accessed 2005 May 11]
  22. 22.
    Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003 Aug; 48(8): 2224–33PubMedCrossRefGoogle Scholar
  23. 23.
    Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005 Feb; 64(2): 229–34PubMedCrossRefGoogle Scholar
  24. 24.
    Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005 May; 44(5): 670–6CrossRefGoogle Scholar
  25. 25.
    Baraliakos X, Brandt J, Listing J, et al. Clinical response to withdrawal of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Clin Exp Rheumatol 2004 Sep–Oct; 22(5): 665Google Scholar
  26. 26.
    Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001 Jul; 28: 1605–14PubMedGoogle Scholar
  27. 27.
    Stone MA, Payne U, Pacheco-Tena C, et al. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. Ann Rheum Dis 2004 Jan; 63(1): 84–7PubMedCrossRefGoogle Scholar
  28. 28.
    Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002 Nov; 41: 1280–5CrossRefGoogle Scholar
  29. 29.
    Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis 2003 Dec; 62(12): 1218–20PubMedCrossRefGoogle Scholar
  30. 30.
    Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade®). Rheumatology (Oxford) 2004 Sep; 43(9): 1158–66CrossRefGoogle Scholar
  31. 31.
    Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994 Dec; 21(12): 2281–5PubMedGoogle Scholar
  32. 32.
    Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001 Aug; 44(8): 1876–86PubMedCrossRefGoogle Scholar
  33. 33.
    Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994 Sep; 21(9): 1694–8PubMedGoogle Scholar
  34. 34.
    Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-α antagonists. Drug Saf 2004; 27(5): 307–24PubMedCrossRefGoogle Scholar
  35. 35.
    Ferraro-Peyret C, Coury F, Tebib JG, et al. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther 2004; 6(6): R535–43PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Adis International LtdMairangi Bay, AucklandNew Zealand

Personalised recommendations